Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Sandra Misale

Has grant

Assistant Professor

Johns Hopkins University School of Medicine

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

Recent Grants

Grant: Open

New specific therapeutic approaches to target NF1-null Melanoma

Open Date: 2025-06-01

Close Date: 2028-05-01

Articles (13)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Anna Trigos

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA

View details

Soren Cole

Johns Hopkins University

UNITED STATES

View details

Teresa Monkkonen

Assistant Professor

San Diego State University

UNITED STATES

View details

Stefan Prekovic

Group leader

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sandra Misale

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (13)

Targeting RAS for Pancreatic Cancer Interception

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma

Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations

The evolving landscape of RAS-targeted therapies

Tackling the next decade of cancer research

The Far Side of Resistance to RAS Inhibitors

Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.

Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma

EGFR-directed antibodies promote HER2 ADC internalization and efficacy

RAS G12C Inhibitors: Three Birds with One Stone

The 2023 generation

Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.

Correction: Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer (Oncogene, (2018), 37, 33, (4599-4610), 10.1038/s41388-018-0289-x)

Collaborators (4)

Anna Trigos

Soren Cole

Teresa Monkkonen

Stefan Prekovic

Make your next move.